Low Apgar Scores Predict Poor Outcomes in Premature Infants
A 5-minute Apgar score < 7 was significantly associated with increased risks for in-hospital mortality, severe intraventricular haemorrhage (IVH), bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), and prolonged hospital stay among infants born very preterm (VPT).
METHODOLOGY:
Researchers conducted a prospective population-based cohort study of liveborn infants born VPT from the EPICE-SHIPS cohort.
This study included 7900 liveborn infants born VPT between 22 + 0 and 31 + 6 weeks of gestation across 19 regions in 11 European countries.
Data on maternal and perinatal characteristics, management, and neonatal outcomes were collected from patient records.
Adjusted associations between 5-minute Apgar scores < 7 and adverse neonatal outcomes were analysed; researchers tested for interactions by the country-level prevalence of an Apgar score < 7, categorised as low (14%-16%), medium (19%-22%), and high (28%-40%) groups.
Outcomes included in-hospital mortality, severe IVH (> grade 2), cystic periventricular leukomalacia (cPVL), necrotising enterocolitis, late-onset infection, ROP (≥ stage 3), BPD (moderate/severe), and prolonged hospital stay.
TAKEAWAY:
A 5-minute Apgar score < 7 was observed in 20.2% of infants born VPT, varying widely across countries from 14% to 40%.
A low Apgar score (< 7) was strongly associated with a higher risk for in-hospital mortality than a high Apgar score (≥ 7; 35.7% vs 6.9%; adjusted relative risk [RR], 2.24; 95% CI, 1.95-2.58), with consistent risk observed across all country groups.
A low Apgar score was associated with increased risks for severe IVH (RR, 1.61; 95% CI, 1.33-1.96), ROP (RR, 1.41; 95% CI, 1.09-1.82), cPVL (RR, 1.40; 95% CI, 1.00-1.96), BPD (RR, 1.35; 95% CI, 1.20-1.51), and prolonged hospital stay (RR, 1.44; 95% CI, 1.26-1.63).
Associations with IVH, BPD, and prolonged hospital stay were stronger among countries with a lower prevalence of low Apgar scores (test of interaction P = .04 for IVH, P = .09 for BPD, and P = .43 for prolonged hospital stay).
IN PRACTICE:
"[Low Apgar scores'] interactions with adverse outcomes demand caution when using the Apgar score in prognostic models for clinical care and research without local validation," the authors wrote.
SOURCE:
This study was led by Harald Ehrhardt, MD, Department of Pediatrics and Adolescent Medicine, University Medical Centre Ulm, Ulm, Germany. It was published online on July 15, 2025, in BJOG: An International Journal of Obstetrics & Gynaecology.
LIMITATIONS:
The study's data were collected in 2011-2012, and clinical practices may have evolved since then. Variations in how Apgar scores were assigned across different centres, the lack of data on postnatal resuscitation efforts, and a mostly White European cohort may have limited generalisability.
DISCLOSURES:
This work was supported by the European Union's (EU's) Seventh Framework Programme and the EU's Horizon 2020 research and innovation programme. Some authors reported receiving funding from the EU and Swedish Foundation related to the study, and others reported receiving unrelated grants and serving unpaid roles in paediatric organisations and advisory boards.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
10 minutes ago
- Fox News
Mosquito-borne virus spreading through China causes high fever, joint pain
A mosquito-borne virus has led to a widespread outbreak in China, sparking concerns about global impact. The U.S. Centers for Disease Control and Prevention (CDC) has issued a Level 2 alert for an outbreak of chikungunya virus in the Guangdong Province, where health officials have reported more than 7,000 cases as of Wednesday, per the AP. The virus spreads when a mosquito feeds on an infected person and then bites another person. There are efforts underway to control the mosquitoes spreading the virus, including the use of nets, insecticide and drones, the report stated. Chikungunya cases have also been spreading throughout Europe, according to the European Centre for Disease Prevention and Control (ECDC). Since the beginning of 2025, approximately 240,000 CHIKVD cases and 90 deaths have been reported in 16 countries and territories, including the Americas, Africa, Asia and Europe, the health agency reported in July. There have been no confirmed locally acquired cases in the U.S. since 2019, according to CDC data. Common symptoms of chikungunya include high fever and joint pain, according to Dr. Marc Siegel, Fox News senior medical analyst. They usually begin between three and seven days after being bitten by an infected mosquito. Some people may also experience headache, joint swelling, rash and muscle pain, the CDC stated. In most cases, symptoms abate within a week, but some may suffer from severe joint pain for months or years after infection. "Occasionally, neurological complications arise, including encephalitis (swelling of the brain)." "Occasionally, neurological complications arise, including encephalitis (swelling of the brain)," Siegel cautioned. People at highest risk of severe illness include adults 65 and older, newborns and people with comorbidities, such as heart disease or diabetes, the CDC said. Chikungunya is rarely fatal. The chikungunya virus is not transmitted among humans, and cannot be spread through physical contact, coughing or sneezing, the CDC stated. While there have been cases of chikungunya in Southeast Asia, the high volume in Southern China is new, Siegel noted. "China's strategy for containment is also very restrictive and draconian, and won't likely work," he told Fox News Digital. The country has shared plans to use drones to seek out standing water where mosquitoes breed, as well as spraying parks, public places and even people with insect repellents, the doctor said. "Officials are going door to door dressed in red vests and fining or arresting anyone who has still water," Siegel said, citing a New York Times report. "They are also quarantining sick people in the hospital for a week under mosquito netting." Another tactic is using elephant mosquitoes, which produce larvae that eat the Aedes mosquitoes that spread the virus, Siegel added. "None of this is likely to work, as people live too close together and these mosquitoes breed easily," he said. There are not currently any specific medications to treat chikungunya virus. The best way to keep the virus at bay is to prevent mosquito bites, according to experts. Recommended prevention strategies include using EPA-registered insect repellent, wearing long-sleeved shirts and pants, keeping screens on windows, using mosquito netting if sleeping outside, and treating clothing and gear with 0.5% permethrin (a synthetic chemical used primarily as an insecticide). For more Health articles, visit Two vaccines are available in the U.S. — a live-attenuated vaccine (IXCHIQ) and a virus-like particle vaccine (VIMKUNYA), which may be recommended for higher-risk travelers who plan to visit places where the virus is prevalent, the CDC stated. Travelers should speak with a healthcare provider to determine whether they are candidates for the vaccine.
Yahoo
an hour ago
- Yahoo
More than 400 indirect deaths linked to LA wildfires, study suggests
More than 400 additional deaths are estimated to be linked to the wildfires that ravaged Los Angeles earlier this year, according to a new study. The figure, published on Wednesday in the medical journal JAMA, looks at deaths that have been attributed to factors caused by the wildfires, like poor air quality and delays in accessing healthcare. It is a higher figure than the official death count of 31 by the Los Angeles County, which tallied deaths caused directly by the fires. The study comes as hundreds of wildfires burn across the US and Canada, prompting air quality advisories in cities like Chicago, Buffalo and New York. The Palisades and Eaton fires tore through Los Angeles in January, destroying thousands of structures and leading to the evacuation of more than 100,000 Los Angeles residents. Why wildfires are becoming faster and more furious The far-reaching impacts of wildfire smoke – and how to protect yourself The latest study revealed that around 440 people are estimated to have died as a result of the wildfires between 5 January and 1 February. Researchers said they tallied the figure by looking at all deaths and their causes in Los Angeles during the period of the fires, and comparing it to similar data from previous years. The results show that there were nearly 7% more deaths during the wildfires. Some are attributed to lung and heart conditions exacerbated by smoke or stress, while others are more indirect - like delayed healthcare treatment for dialysis or cancer patients as a result of fire-related disruptions. The authors said that the findings underscore the need for officials to count both direct and indirect fatalities of wildfires and other climate-related emergencies when trying to quantify their impact. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies," the authors said, noting that their figures are provisional as there may have been additional fire-related deaths beyond the scope of the study. The BBC has reached out to Los Angeles County officials for comment on the study's findings. Another study released on Wednesday in JAMA that looked at the aftermath of the 2023 Maui wildfires showed that 22% of adults in the region had reduced lung function, and half displayed symptoms of depression. The fires, which broke out in August 2023 and were the worst to affect Hawaii in recent history, killed at least 102 people and destroyed more than 2,000 structures. The authors of the Maui study said their results show the need for "sustained clinical monitoring and community-based mental health supports" months after a climate disaster. A second study on the Hawaii fires suggests that Maui saw the highest suicide and drug overdose rates in the month of the 2023 wildfires. Wildfires have become more frequent in recent years as a result of climate change, driven by hotter and drier weather that fuels fire spread. In addition to directly threatening lives and structures, smoke from wildfires has been shown to have adverse health effects on people. Wildfire smoke has been found to be harmful to certain immune cells in the lungs, with a toxicity four times greater than particulates from other types of pollution. This can have a long-term impact on cardiovascular health, experts have said. Older people, pregnant women and young children, as well as those with underlying health conditions, such as heart disease or asthma, are more likely to get sick, experts say. But the smoke can also impact healthy adults. One dead and thousands evacuated as wildfire spreads in France Massive clouds of smoke blanket parts of California as Gifford fire grows Canadian wildfires prompt New York air quality alert Ten workers killed battling wildfires in Turkey
Yahoo
3 hours ago
- Yahoo
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk (NVO) reported an earnings miss Wednesday, sending its stock down 4% in early trading, pressuring the stock further after a surprise management shake-up earlier in the year and sharply lowered guidance despite growing sales of its blockbuster GLP-1 drugs Ozempic and Wegovy. The stock is down more than 46% year to date as a result. CFO Karsten Munk Knudsen discussed some of the changes in recent weeks. He told Yahoo Finance that the leadership change — the ousting of CEO Lars Jørgensen and international head Mike Doustdar taking his place — was a surprise. "I was surprised about the changes of CEOs back in May," Knudsen said. "But ... looking at other companies ... when pressure is on, in terms of performance and competition, then it's not unusual that bosses and owners assess what's the right team to lead the company. In a macro setting I don't think its extraordinary, but in a Novo setting it was indeed surprising." The US market has also proven a challenge for Novo Nordisk, as it lost its lead despite a first-mover advantage to competitor Eli Lilly (LLY). Executives blame the compounding market, in which copycats are allowed under special circumstances, with telehealth platforms taking advantage of the loophole despite the FDA ending a shortage of GLP-1s that previously allowed copycats to freely sell on the market. Knudsen said the compounding market is about one-third of current GLP-1 prescriptions in the US market. On top of the competition and copycats, Novo Nordisk, like other big pharma names, has been targeted by the Trump administration to lower prices for consumers. It was one of 17 companies to receive a letter demanding lower costs for current and new products. "In reality, we're not that far apart in the sense that we also drive for affordable access in products that we supply. Our GLP-1 pricing is already rather low," Knudsen said, without revealing the actual numbers. Outgoing CEO Lars Jørgensen said on an earnings call Wednesday that its prices for Medicaid, for example, are already lower than in Europe. Those prices are not publicly available. The letter also asked the companies to price new drugs at the same low pricing found in other developed countries and to provide the lower cash prices more widely. Crunching cash numbers Some experts have expressed doubt about cash market success, however. Craig Garthwaite, a professor of strategy and healthcare at Northwestern University's Kellogg School of Management, posted on X in response to the Trump letters, questioning the strategy's viability. "How many customers do we believe have the ability (or willingness) to pay out of pocket for brand name drugs? A simple reading of the literature on increasing cost sharing suggests that people are not prepared to pay cash for these products — even if it is at the net and not the list price," Garthwaite said. But Knudsen noted that of its Wegovy patients in the US, 10% are paying cash through NovoCare, the direct-to-consumer channel, after it launched in March. "I am absolutely convinced that the cash channel is going to increase from here, and going to constitute a major part of the Wegovy business into the future," he said, adding that the overall cash market for GLP-1 in the US is already way above 10%. Knudsen referenced the compounding market, saying it provides insight into the potential, as those customers are cash-paying and represent one-third of the Wegovy market. But the cash price paid for copycats is significantly lower than the $499 per month available on NovoCare. Hims and Hers (HIMS), which Novo recently cut ties with over its refusal to stop selling compounded semaglutide, advertises prices as low as $199 per month for a 12-month plan of the copycat drug. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
